Сost-effectiveness of pentavalent rotavirus vaccination in the Russian Federation

Author:

Rudakova A. V.1,Kharit S. M.1,Rychkova S. V.1,Lobzin Yu. V.1

Affiliation:

1. Pediatric Research and Clinical Center for Infectious Diseases

Abstract

   One of the main causes of acute gastroenteritis in children under 5 years of age is rotavirus infection (RVI). Vaccines against RVI significantly reduce the incidence.   Aim. To evaluate the cost-effectiveness of mass vaccination of children with a 5-valent RVI vaccine in the Russian Federation.   Materials and methods. The assessment was carried out using modeling based on published data on the effectiveness of the vaccine and epidemiological indicators in the Russian Federation. The analysis was carried out from the perspective of the health care system and society as a whole with a 5-year horizon. The cost of RVI therapy corresponded to the compulsory health insurance tariffs for St. Petersburg for 2022, the price of 1 dose of the vaccine was the registered price, including VAT. Costs and life expectancy, taking into account quality, were discounted at 3.5 % per year.   Results. Given the assumptions made, routine vaccination will prevent an average of 468,637 cases of RVI over 5 years. Avoided direct medical costs, i. e. RVI treatment costs will amount to 53,4 %, and lost income due to temporary disability – 46,6 % of the total avoided costs. At the same time, the volume of avoided costs is 61,4 % due to a decrease in morbidity in the vaccinated population, and 38.6 % due to the development of a indirect effect. The predicted avoided costs per 1 vaccinated person is 2,975 thousand rubles. From a societal perspective, the cost-effectiveness of the Rota-V-Aid vaccine will be 364,813 thousand rubles / QALY (quality-adjusted life year), and from a healthcare perspective – 1726,399 thousand rubles / QALY. Thus, in both cases, the cost-effectiveness of RVI vaccination will not exceed the generally accepted threshold of willingness to pay, equal to three times the gross domestic product per capita in the Russian Federation (according to data for 2021 – ~2,7 million rubles). The predicted cost-effectiveness of selective vaccination is significantly lower than that of mass vaccination.   Conclusions. Mass vaccination of children with a 5-valent vaccine against RVI will not only reduce the incidence in the Russian Federation, but, taking into account the assumptions made, can also be considered as a cost-effective intervention.

Publisher

SPRIDA

Subject

Infectious Diseases

Reference47 articles.

1. Vasil’ev B. Ya., Vasil’eva R. I., Lobzin Yu. V. Ostrye kishechnye zabolevaniya. Rotavirusy i rotavirusnaya infekciya. — SPb., 2000.

2. World Health Organisation, Rotavirus vaccines. WHO Position Paper–January 2013. Wkly Epidemiol Rec 2013; 88 (5): 49–64.

3. Podkolzin A. T., Fenske E. B., Abramycheva N. Y. et al. Hospital-based surveillance of rotavirus and other viral agents of diarrhea in children and adults in Russia, 2005-2007 // J Infect Dis. 2009 Nov 1; 200 Suppl 1:S228-33. doi: 10.1086/605054.

4. Podkolzin A. T. Epidemiologicheskaya i klinicheskaya harakteristika ostryh kishechnyh infekcij virusnoj etiologii v Rossijskoj Fedeeracii. - Avtoref. dis. … d. m. n..- Moskva. - FGBU «CNII epidemiologii» Rospotrebnadzora. - 46 s.

5. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2021 godu: Gosudarstvennyj doklad. M.: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebitelej i blagopoluchiya cheloveka, 2022. 340 s.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3